TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 54.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,775 shares of the biopharmaceutical company's stock after purchasing an additional 8,338 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in TG Therapeutics were worth $898,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. Clearbridge Investments LLC purchased a new stake in TG Therapeutics in the fourth quarter valued at approximately $55,237,000. Raymond James Financial Inc. purchased a new stake in TG Therapeutics in the fourth quarter valued at approximately $14,508,000. Norges Bank purchased a new stake in TG Therapeutics in the fourth quarter valued at approximately $12,085,000. Penn Capital Management Company LLC purchased a new stake in TG Therapeutics in the fourth quarter valued at approximately $10,577,000. Finally, First Trust Advisors LP increased its position in shares of TG Therapeutics by 871.7% during the fourth quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock worth $8,292,000 after acquiring an additional 247,145 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Down 1.5%

TGTX traded down $0.58 on Friday, hitting $37.09. 957,440 shares of the company were exchanged, compared to its average volume of 2,882,684. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. The firm has a 50-day moving average price of $36.18 and a two-hundred day moving average price of $35.25. The company has a market cap of $5.89 billion, a price-to-earnings ratio of 154.54 and a beta of 1.91. TG Therapeutics, Inc. has a twelve month low of $16.65 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business's revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.07) EPS. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.64% of the company's stock.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $43.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.